Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. (2021)

First Author: Ramasamy MN

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(20)32466-1

PubMed Identifier: 33220855

Publication URI: http://europepmc.org/abstract/MED/33220855

Type: Journal Article/Review

Volume: 396

Parent Publication: Lancet (London, England)

Issue: 10267

ISSN: 0140-6736